Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943004 · ClinicalTrials.gov registry record · Phase 1
Trial of DFP-14927 in Advanced Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, sponsored by Delta-Fly Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT03943004: Recruiting Phase 1 study of Cancer and Solid Tumor, sponsored by Delta-Fly Pharma.
NCT03943004 is a Phase 1 study of Cancer and Solid Tumor that is actively recruiting participants, run by Delta-Fly Pharma. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943004, a Phase 1 study of Cancer and Solid Tumor, is actively recruiting participants, sponsored by Delta-Fly Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
Primary Outcome
The highest dose level at which less than one-third of at least 6 patients (i.e., 0 or 1 out of 6) experience a DLT
Conditions Studied
Interventions
- DRUG DFP-14927
Study Locations (2)
California
- UCLA Department of Medicine- Hematology/Oncology - Los Angeles
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 1 |
What NCT03943004 shows while recruiting
NCT03943004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which DFP-14927 is the first listed.
NCT03943004 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT03943004 about?
NCT03943004 is a clinical study titled "Trial of DFP-14927 in Advanced Solid Tumors". This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
What is the current status of trial NCT03943004?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-09-30. Estimated completion is 2026-06-01.
What conditions does trial NCT03943004 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor.
What interventions are being tested in trial NCT03943004?
The interventions under investigation include: DFP-14927 (DRUG).
Who is sponsoring clinical trial NCT03943004?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943004 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03943004's enrollment target sits among peer trials
30 502nd of 615 higher than 93 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI